Pfizer Stock Price, News & Analysis (NYSE:PFE)

$36.54 -0.02 (-0.05 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$36.56
Today's Range$36.46 - $36.80
52-Week Range$30.90 - $37.35
Volume19.20 million shs
Average Volume15.64 million shs
Market Capitalization$218.16 billion
P/E Ratio22.42
Dividend Yield3.50%
Beta1.01

About Pfizer (NYSE:PFE)

Pfizer logoPfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:PFE
CUSIP71708110
Phone+1-212-5732323

Debt

Debt-to-Equity Ratio0.56%
Current Ratio1.43%
Quick Ratio1.15%

Price-To-Earnings

Trailing P/E Ratio22.4171779141104
Forward P/E Ratio14.11
P/E Growth2.44

Sales & Book Value

Annual Sales$52.82 billion
Price / Sales4.12
Cash Flow$3.38 per share
Price / Cash10.81
Book Value$9.86 per share
Price / Book3.71

Profitability

Trailing EPS$1.63
Net Income$7.22 billion
Net Margins18.69%
Return on Equity25.41%
Return on Assets8.90%

Miscellaneous

Employees96,500
Outstanding Shares5,960,710,000

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 18th. Investors of record on Friday, February 2nd will be paid a dividend of $0.34 per share on Thursday, March 1st. This represents a $1.36 annualized dividend and a yield of 3.72%. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer's previous quarterly dividend of $0.32. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has approved a share buyback plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Tuesday, October, 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The biopharmaceutical company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business's revenue was up .9% compared to the same quarter last year. During the same period last year, the company posted $0.61 earnings per share. View Pfizer's Earnings History.

When will Pfizer make its next earnings announcement?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, January, 30th 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY17 earnings guidance on Tuesday, October, 31st. The company provided earnings per share (EPS) guidance of $2.58-2.62 for the period, compared to the Thomson Reuters consensus estimate of $2.56. The company issued revenue guidance of $52.4-53.1 billion, compared to the consensus revenue estimate of $52.76 billion.

Where is Pfizer's stock going? Where will Pfizer's stock price be in 2018?

17 Wall Street analysts have issued 12 month price targets for Pfizer's stock. Their predictions range from $31.00 to $53.00. On average, they expect Pfizer's stock price to reach $38.80 in the next year. View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

  • 1. According to Zacks Investment Research, "Pfizer is facing headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Additionally, Pfizer’s shares have underperformed the industry this year so far. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. The company has a mixed record of earnings surprises in recent quarters. Estimates have remained stable ahead of its Q3 earnings results." (10/11/2017)
  • 2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)
  • 3. UBS Group AG analysts commented, " The FDA approved Novartis' CDK4/6 agent, Kisqali (ribociclib), in first-line treatment for HR+/HER2- metastatic breast cancer in combo with any aromatase inhibitor. Recall that MONALEESA-2 was stopped early, and while interim data demonstrated a reduction in risk of disease progression or death by 44% over letrozole alone, the mPFS had not been reached at the time. For the first time, the label presented a mPFS of 25.3 mos for Kisqali + letrozole vs 16 mos for letrozole alone. The 9.3 mos improvement over letrozole is essentially comparable to 10.3 mos improvement (24.8 mos for Ibrance vs 14.5 mos for letrozole) for Pfizer's Ibrance. Given the strong interim data that were comparable to Ibrance, we believe the approval of Kisqali was largely expected. Our takeaway: Label looks a little worse than Ibrance. Overall, we think the label looks slightly worse, particularly on safety. On the positive, the label is broader, as the indication is for use of Kisqali in combo with anyaromatase inhibitors (vs Ibrance in combo with letrozole). However, as the vast majority of first-line use letrozole, the broader label shouldn't meaningfully impact Ibrance, in our view. We're not clear on how Kisqali got the broader label, but we think this could be encouraging for Ibrance, as the Ibrance label could also become as broad with the potential April approval of the confirmatory Phase 3 PALOMA-2 (Ibrance was approved under an accelerated pathway with Phase 2 PALOMA-1 data). On safety, the Kisqali label warns of QT prolongation and liver tox, which are not in the Ibrance label. We think the QT issue could put Kisqali at a disadvantage. Thoughts on the stock: Shouldn't impact the stock much, if anyIbrance has been on the market for ~2 years and has made significant headway to becoming a standard of therapy, and we do not believe there was anything in the Kisqali label that would meaningfully impact the significant lead that Pfizer has. In our CDK4/6 model, we assign a 5% share for Kisqali in 2017 that goes to 15%, 18%, and 20% in 2018-2020E." (3/14/2017)
  • 4. Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)

Are investors shorting Pfizer?

Pfizer saw a drop in short interest in the month of December. As of December 29th, there was short interest totalling 49,905,703 shares, a drop of 16.4% from the December 15th total of 59,697,345 shares. Based on an average trading volume of 11,834,320 shares, the days-to-cover ratio is currently 4.2 days. Approximately 0.8% of the company's shares are short sold.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

  • Ian C. Read, Chairman of the Board, Chief Executive Officer (Age 63)
  • Frank A. D'Amelio, Chief Financial Officer, Executive Vice President - Business Operations (Age 59)
  • Mikael Dolsten M.D., Ph.D., President - Worldwide Research and Development (Age 58)
  • Angela Hwang, Group President - Pfizer Essential Health (Age 52)
  • John D. Young, Group President - Pfizer Innovative Health and Angela Hwang (Age 53)
  • Albert Bourla, Chief Operating Officer (Age 56)
  • Rady A. Johnson II, Executive Vice President, Chief Compliance and Risk Officer (Age 55)
  • Douglas M. Lankler, Executive Vice President, General Counsel (Age 51)
  • Charles H. Hill III, Executive Vice President - Worldwide Human Resources (Age 61)
  • Freda C. Lewis-Hall M.D., Executive Vice President, Chief Medical Officer (Age 62)

Who owns Pfizer stock?

Pfizer's stock is owned by a number of of retail and institutional investors. Top institutional investors include Hexavest Inc. (0.12%), Confluence Investment Management LLC (0.04%), Nisa Investment Advisors LLC (0.04%), Foundation Resource Management Inc. (0.02%), Sit Investment Associates Inc. (0.02%) and Exxonmobil Investment Management Inc. TX (0.02%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson and Sally Susman. View Institutional Ownership Trends for Pfizer.

Who sold Pfizer stock? Who is selling Pfizer stock?

Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Foundation Resource Management Inc., LVM Capital Management Ltd. MI, Exxonmobil Investment Management Inc. TX, Nisa Investment Advisors LLC, Private Capital Advisors Inc., Starfire Investment Advisers Inc., First Citizens Bank & Trust Co. and Atalanta Sosnoff Capital LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Frank A Damelio, Ian C Read, Laurie J Olson, Mikael Dolsten, Rady A Johnson and Sally Susman. View Insider Buying and Selling for Pfizer.

Who bought Pfizer stock? Who is buying Pfizer stock?

Pfizer's stock was acquired by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co, DnB Asset Management AS, USS Investment Management Ltd, Hexavest Inc., Country Trust Bank, Sit Investment Associates Inc., Confluence Investment Management LLC and First American Trust FSB. View Insider Buying and Selling for Pfizer.

How do I buy Pfizer stock?

Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of Pfizer stock can currently be purchased for approximately $36.54.

How big of a company is Pfizer?

Pfizer has a market capitalization of $218.16 billion and generates $52.82 billion in revenue each year. The biopharmaceutical company earns $7.22 billion in net income (profit) each year or $1.63 on an earnings per share basis. Pfizer employs 96,500 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 E 42ND ST, NEW YORK, NY 10017-5703, United States. The biopharmaceutical company can be reached via phone at +1-212-5732323.


MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  899 (Vote Outperform)
Underperform Votes:  471 (Vote Underperform)
Total Votes:  1,370
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfizer (NYSE:PFE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.532.562.502.42
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.80$38.60$38.20$38.00
Price Target Upside: 6.19% upside5.87% upside5.12% upside13.03% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Jefferies GroupSet Price TargetNeutral$40.00LowView Rating Details
1/8/2018BMO Capital MarketsSet Price TargetBuy$39.00LowView Rating Details
1/5/2018Morgan StanleySet Price TargetBuy$41.00LowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/6/2017Deutsche BankSet Price TargetBuy$38.00LowView Rating Details
11/1/2017JPMorgan Chase & Co.Set Price TargetBuy$39.00N/AView Rating Details
11/1/2017Goldman Sachs GroupSet Price TargetNeutral$36.00N/AView Rating Details
10/31/2017Berenberg BankSet Price TargetNeutral$36.00N/AView Rating Details
10/11/2017BarclaysSet Price TargetBuy$38.00N/AView Rating Details
9/19/2017Sanford C. BernsteinSet Price TargetBuy$39.00LowView Rating Details
8/14/2017CowenSet Price TargetBuy$43.00LowView Rating Details
7/20/2017Credit Suisse GroupDowngradeOutperform -> Neutral$38.00 -> $36.00LowView Rating Details
5/16/2017CitigroupDowngradeNeutral -> Sell$38.00 -> $31.00LowView Rating Details
3/23/2017Societe GeneraleReiterated RatingNeutral$36.00LowView Rating Details
2/2/2017MorningstarReiterated RatingBuyN/AView Rating Details
2/1/2017Atlantic SecuritiesSet Price TargetBuy$37.00N/AView Rating Details
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$53.00N/AView Rating Details
12/2/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
11/7/2016Bank of AmericaReiterated RatingBuy$40.00 -> $36.00N/AView Rating Details
11/2/2016ArgusDowngradeBuy -> HoldN/AView Rating Details
5/4/2016Independent ResearchSet Price TargetNeutral$37.00N/AView Rating Details
5/2/2016Leerink SwannLower Price TargetMarket Perform$37.00 -> $34.70N/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
2/16/2016SunTrust BanksLower Price TargetNeutral$37.00 -> $33.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/29/2018N/AView Earnings Details
10/31/2017Q3 2017$0.65$0.67$13.17 billion$13.17 billionViewN/AView Earnings Details
8/1/2017Q2 2017$0.65$0.67$13.08 billion$12.90 billionViewListenView Earnings Details
5/2/2017Q1 2017$0.67$0.69$13.09 billion$12.78 billionViewListenView Earnings Details
1/31/2017Q416$0.50$0.47$13.64 billion$13.60 billionViewN/AView Earnings Details
11/1/2016Q3$0.62$0.61$13.05 billion$13.05 billionViewN/AView Earnings Details
8/2/2016Q216$0.62$0.64$13.01 billion$13.10 billionViewN/AView Earnings Details
5/3/2016Q116$0.55$0.67$12.00 billion$13.00 billionViewN/AView Earnings Details
2/2/2016Q415$0.52$0.53$13.57 billion$14.05 billionViewN/AView Earnings Details
10/27/2015Q315$0.51$0.60$11.56 billion$12.10 billionViewListenView Earnings Details
7/28/2015Q215$0.52$0.56$11.39 billion$11.00 billionViewListenView Earnings Details
4/28/2015Q115$0.49$0.51$10.79 billion$10.86 billionViewN/AView Earnings Details
1/27/2015Q414$0.53$0.54$12.94 billion$13.10 billionViewN/AView Earnings Details
10/28/2014Q314$0.55$0.57$12.24 billion$12.40 billionViewN/AView Earnings Details
7/29/2014Q214$0.57$0.58$12.49 billion$12.80 billionViewN/AView Earnings Details
5/5/2014Q114$0.56$0.57$12.07 billion$11.35 millionViewN/AView Earnings Details
1/27/2014Q413$0.52$0.56$13.35 billion$13.56 billionViewN/AView Earnings Details
10/29/2013Q313$0.56$0.58$12.69 billion$12.64 billionViewN/AView Earnings Details
7/30/2013Q2 2013$0.55$0.56$13.02 billion$12.97 billionViewListenView Earnings Details
4/30/2013Q1 2013$0.55$0.54$14.10 billion$13.50 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.44$0.47$14.40 billion$15.10 billionViewListenView Earnings Details
11/1/2012Q312$0.53$0.53$14.64 billion$14.00 billionViewN/AView Earnings Details
7/31/2012$0.54$0.62ViewN/AView Earnings Details
5/1/2012$0.57$0.58ViewN/AView Earnings Details
1/31/2012$0.47$0.50ViewN/AView Earnings Details
11/1/2011$0.55$0.62ViewN/AView Earnings Details
8/2/2011$0.59$0.60ViewN/AView Earnings Details
5/3/2011$0.59$0.60ViewN/AView Earnings Details
2/1/2011$0.46$0.47ViewN/AView Earnings Details
11/2/2010Q3 2010$0.51$0.54ViewN/AView Earnings Details
8/3/2010Q2 2010$0.52$0.62ViewN/AView Earnings Details
5/4/2010Q1 2010$0.53$0.60ViewN/AView Earnings Details
2/3/2010Q4 2009$0.49$0.49ViewN/AView Earnings Details
10/20/2009Q3 2009$0.48$0.51ViewN/AView Earnings Details
7/22/2009Q2 2009$0.46$0.48ViewN/AView Earnings Details
4/28/2009Q1 2009$0.48$0.54ViewN/AView Earnings Details
1/26/2009Q4 2008$0.60$0.65ViewN/AView Earnings Details
10/21/2008Q3 2008$0.60$0.62ViewN/AView Earnings Details
7/23/2008Q2 2008$0.54$0.55ViewN/AView Earnings Details
4/17/2008Q1 2008$0.65$0.61ViewN/AView Earnings Details
1/23/2008Q4 2007$0.47$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pfizer (NYSE:PFE) Earnings Estimates

Current Year EPS Consensus Estimate: $2.59 EPS
Next Year EPS Consensus Estimate: $2.74 EPS

Dividends

Pfizer (NYSE:PFE) Dividend Information

Next Dividend:3/1/2018
Annual Dividend:$1.28
Dividend Yield:3.50%
Dividend Growth:7.20% (3 Year Average)
Payout Ratio:78.53% (Trailing 12 Months of Earnings)
49.42% (Based on This Year's Estimates)
46.72% (Based on Next Year's Estimates)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/18/2017quarterly$0.343.68%2/1/20182/2/20183/1/2018
9/27/2017quarterly$0.323.6%11/9/201711/10/201712/1/2017
6/22/2017quarterly$0.323.75%8/2/20178/4/20179/1/2017
4/28/2017quarterly$0.323.77%5/10/20175/12/20176/1/2017
12/12/2016quarterly$0.323.9%2/1/20172/3/20173/1/2017
9/23/2016quarterly$0.303.5%11/8/201611/11/201612/1/2016
6/23/2016quarterly$0.303.53%8/3/20168/5/20169/1/2016
4/28/2016quarterly$0.303.67%5/11/20165/13/20166/1/2016
12/14/2015quarterly$0.303.72%2/3/20162/5/20163/2/2016
9/25/2015quarterly$0.283.63%11/4/201511/6/201512/1/2015
6/25/2015quarterly$0.283.3%8/5/20158/7/20159/2/2015
4/23/2015quarterly$0.283.18%5/6/20155/8/20156/2/2015
12/15/2014quarterly$0.283.65%2/4/20152/6/20153/3/2015
10/23/2014quarterly$0.263.57%11/5/201411/7/201412/2/2014
6/26/2014quarterly$0.263.51%7/30/20148/1/20149/3/2014
4/25/2014quarterly$0.263.38%5/7/20145/9/20146/3/2014
12/16/2013quarterly$0.263.45%2/5/20142/7/20143/4/2014
10/24/2013quarterly$0.243.14%11/6/201311/8/201312/3/2013
6/27/2013quarterly$0.243.43%7/31/20138/2/20139/4/2013
4/25/2013quarterly$0.243.19%5/8/20135/10/20136/4/2013
12/17/2012quarterly$0.243.74%1/30/20132/1/20133/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 69.75%
Insider Trades by Quarter for Pfizer (NYSE:PFE)
Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Alexander R MackenzieInsiderSell6,750$37.00$249,750.00103,458View SEC Filing  
12/15/2017Rady A JohnsonEVPSell8,000$37.07$296,560.0046,963View SEC Filing  
11/1/2017Alexander R MackenzieInsiderSell14,700$35.30$518,910.00117,432View SEC Filing  
10/2/2017Alexander R MackenzieEVPSell7,350$35.65$262,027.50117,432View SEC Filing  
9/12/2017Sally SusmanInsiderSell38,230$35.00$1,338,050.00145,649View SEC Filing  
9/1/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00124,774View SEC Filing  
8/31/2017Alexander R MackenzieInsiderSell7,350$34.00$249,900.00132,124View SEC Filing  
8/31/2017Frank A DamelioEVPSell94,409$34.00$3,209,906.00337,389View SEC Filing  
8/31/2017Ian C ReadCEOSell197,168$34.00$6,703,712.00580,318View SEC Filing  
8/21/2017Laurie J OlsonInsiderSell8,064$32.70$263,692.8074,506View SEC Filing  
8/7/2017Alexander R MackenzieInsiderSell15,000$33.50$502,500.00151,474View SEC Filing  
8/4/2017Ian C. ReadCEOSell96,950$34.00$3,296,300.00View SEC Filing  
3/10/2017Rady A JohnsonInsiderSell4,500$34.19$153,855.0054,963View SEC Filing  
3/9/2017Charles H HillInsiderSell36,000$34.07$1,226,520.0057,329View SEC Filing  
3/2/2017Mikael DolstenInsiderSell30,970$34.51$1,068,774.7064,719View SEC Filing  
11/9/2016Anthony J MaddalunaInsiderSell10,000$33.00$330,000.00112,087View SEC Filing  
11/4/2016Albert BourlaInsiderSell18,390$30.05$552,619.50149,199View SEC Filing  
5/26/2016Frank A DamelioEVPSell100,000$34.49$3,449,000.00472,994View SEC Filing  
5/24/2016Loretta V CangialosiVPSell86,000$33.97$2,921,420.00271,663View SEC Filing  
5/11/2016Laurie J OlsonEVPSell4,700$33.50$157,450.0071,659View SEC Filing  
5/10/2016Frank A DamelioEVPSell192,000$33.66$6,462,720.00564,994View SEC Filing  
5/10/2016John D YoungInsiderSell41,700$33.53$1,398,201.00200,399View SEC Filing  
5/9/2016Anthony J MaddalunaEVPSell8,950$33.75$302,062.5088,922View SEC Filing  
5/9/2016Ian C ReadCEOSell275,000$33.80$9,295,000.001,446,738View SEC Filing  
5/5/2016Sally SusmanEVPSell76,116$33.75$2,568,915.00195,951View SEC Filing  
5/4/2016Douglas M LanklerEVPSell29,700$33.69$1,000,593.00124,920View SEC Filing  
5/4/2016Mikael DolstenInsiderSell67,588$33.46$2,261,494.48438,107View SEC Filing  
5/3/2016Frank A DamelioEVPSell87,079$33.65$2,930,208.35372,994View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.002,489,364View SEC Filing  
6/11/2015Laurie J OlsonEVPSell26,000$34.39$894,140.00View SEC Filing  
3/12/2015Sally SusmanEVPSell46,179$34.00$1,570,086.00View SEC Filing  
2/13/2015Loretta V CangialosiVPSell104,000$34.73$3,611,920.00View SEC Filing  
2/12/2015Anthony J MaddalunaEVPSell9,000$34.85$313,650.00View SEC Filing  
2/11/2015Frank A DamelioEVPSell14,800$34.30$507,640.00View SEC Filing  
2/10/2015Anthony J MaddalunaEVPSell9,000$33.78$304,020.00View SEC Filing  
12/8/2014Anthony J MaddalunaEVPSell6,500$32.00$208,000.00View SEC Filing  
11/10/2014Charles H HillEVPSell8,285$30.18$250,041.30View SEC Filing  
11/7/2014John D YoungInsiderSell21,600$29.89$645,624.00View SEC Filing  
10/29/2014Anthony J MaddalunaEVPSell2,425$29.56$71,683.00View SEC Filing  
6/12/2014Laurie J OlsonEVPSell36,275$29.53$1,071,200.75View SEC Filing  
6/2/2014Geno J GermanoInsiderSell30,000$29.68$890,400.00View SEC Filing  
3/17/2014John YoungInsiderSell9,000$31.38$282,420.0099,647View SEC Filing  
3/4/2014Loretta CangialosiVPSell102,943$32.05$3,299,323.15171,756View SEC Filing  
3/4/2014Mikael DolstenInsiderSell35,789$32.58$1,166,005.62344,571View SEC Filing  
3/4/2014Sally SusmanEVPSell67,585$32.59$2,202,595.15173,637View SEC Filing  
1/13/2014Frank DamelioEVPSell131,810$30.82$4,062,384.20356,451View SEC Filing  
11/1/2013Anthony J MaddalunaEVPSell43,500$31.02$1,349,370.00View SEC Filing  
11/1/2013Loretta V CangialosiVPSell10,000$31.20$312,000.00View SEC Filing  
10/28/2013Ian C ReadCEOSell338,000$30.57$10,332,660.00View SEC Filing  
9/16/2013Freda Lewis-HallEVPSell38,461$28.70$1,103,830.70118,383View SEC Filing  
7/31/2013Charles H HillEVPSell96,500$29.64$2,860,260.00View SEC Filing  
7/31/2013Loretta V CangialosiVPSell14,688$29.63$435,205.44View SEC Filing  
5/15/2013Amy W SchulmanEVPSell70,000$29.36$2,055,200.00View SEC Filing  
5/15/2013Ian C ReadCEOSell69,900$29.39$2,054,361.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pfizer (NYSE PFE) News Headlines

Source:
DateHeadline
See Which Of The Latest 13F Filers Holds PfizerSee Which Of The Latest 13F Filers Holds Pfizer
www.nasdaq.com - January 16 at 4:33 PM
See what the IHS Markit Score report has to say about Pfizer Inc.See what the IHS Markit Score report has to say about Pfizer Inc.
finance.yahoo.com - January 16 at 10:23 AM
Pfizer (PFE) Given a $40.00 Price Target at Jefferies GroupPfizer (PFE) Given a $40.00 Price Target at Jefferies Group
www.americanbankingnews.com - January 16 at 9:34 AM
Short Interest in Pfizer Inc. (PFE) Drops By 16.4%Short Interest in Pfizer Inc. (PFE) Drops By 16.4%
www.americanbankingnews.com - January 16 at 2:56 AM
Where’s Mine? Workers Wonder If Trump Tax Cut Will Trickle DownWhere’s Mine? Workers Wonder If Trump Tax Cut Will Trickle Down
finance.yahoo.com - January 12 at 10:23 AM
Parkinson's Disease Space Again Under Spotlight This WeekParkinson's Disease Space Again Under Spotlight This Week
finance.yahoo.com - January 12 at 10:23 AM
3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher
investorplace.com - January 12 at 6:48 AM
A Look At Big Pharmas Value Sensitivity To Changes In Tax RatesA Look At Big Pharma's Value Sensitivity To Changes In Tax Rates
finance.yahoo.com - January 11 at 4:41 PM
Pfizer Ends Its Neuroscience Program—What Does it Mean For Alzheimers?Pfizer Ends Its Neuroscience Program—What Does it Mean For Alzheimer's?
www.huffingtonpost.com - January 11 at 10:47 AM
Approval of Alecensa in Europe Could Boost Roche’s Revenue GrowthApproval of Alecensa in Europe Could Boost Roche’s Revenue Growth
finance.yahoo.com - January 11 at 10:47 AM
Miles White's Bold Moves Made Abbott Laboratories A Global ForceMiles White's Bold Moves Made Abbott Laboratories A Global Force
finance.yahoo.com - January 11 at 10:47 AM
What Does Teva’s Recently Announced Restructuring Plan Entail?What Does Teva’s Recently Announced Restructuring Plan Entail?
finance.yahoo.com - January 11 at 10:47 AM
$13.67 Billion in Sales Expected for Pfizer Inc. (PFE) This Quarter$13.67 Billion in Sales Expected for Pfizer Inc. (PFE) This Quarter
www.americanbankingnews.com - January 10 at 8:48 PM
Why Nestle Is Eyeing Merck's Consumer Health UnitWhy Nestle Is Eyeing Merck's Consumer Health Unit
finance.yahoo.com - January 10 at 4:33 PM
Pfizer Inc. (PFE) Given Consensus Rating of "Buy" by BrokeragesPfizer Inc. (PFE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 10 at 6:02 AM
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia PacificBasilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
feeds.benzinga.com - January 10 at 3:48 AM
Glaxo may be interested in Pfizers consumer products unit at the right priceGlaxo may be interested in Pfizer's consumer products unit at the right price
seekingalpha.com - January 9 at 5:25 PM
Pfizer (PFE) Sales Growth Hamper RatingPfizer (PFE) Sales Growth Hamper Rating
investorplace.com - January 9 at 12:37 PM
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its PastThe 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
finance.yahoo.com - January 9 at 10:16 AM
What Drove Pfizer’s Growth in 3Q17What Drove Pfizer’s Growth in 3Q17
finance.yahoo.com - January 8 at 4:39 PM
Pfizer to Exit Neuro Research, May Create Finance ArmPfizer to Exit Neuro Research, May Create Finance Arm
finance.yahoo.com - January 8 at 4:39 PM
Pfizer to Stall R&D for Alzheimers/Parkinsons, Cut JobsPfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
www.zacks.com - January 8 at 10:33 AM
Alzheimers takes Another Hit as Pfizer Ends Research in this AreaAlzheimer's takes Another Hit as Pfizer Ends Research in this Area
www.nasdaq.com - January 8 at 10:33 AM
How Pfizer’s Business Segments Performed in 3Q17How Pfizer’s Business Segments Performed in 3Q17
finance.yahoo.com - January 8 at 10:33 AM
Wired News – Pfizer Signs SuperHuman Platform License Agreement with Distributed BioWired News – Pfizer Signs SuperHuman Platform License Agreement with Distributed Bio
finance.yahoo.com - January 8 at 10:33 AM
Pfizer’s Performance across Geographies in 3Q17Pfizer’s Performance across Geographies in 3Q17
finance.yahoo.com - January 8 at 10:33 AM
Pfizer Inc. Announces Expiration and Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of ConsentsPfizer Inc. Announces Expiration and Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents
finance.yahoo.com - January 8 at 10:33 AM
Pfizer Inc. (PFE) Expected to Announce Earnings of $0.56 Per SharePfizer Inc. (PFE) Expected to Announce Earnings of $0.56 Per Share
www.americanbankingnews.com - January 8 at 1:28 AM
Pfizer to Cut 300 Jobs as Alzheimers, Parkinsons Research EndsPfizer to Cut 300 Jobs as Alzheimer's, Parkinson's Research Ends
finance.yahoo.com - January 7 at 9:39 PM
[$$] Pfizer Ends Hunt for Drugs to Treat Alzheimer’s and Parkinson’s[$$] Pfizer Ends Hunt for Drugs to Treat Alzheimer’s and Parkinson’s
finance.yahoo.com - January 7 at 9:39 PM
The Wall Street Journal: Pfizer abandons costly hunt for new Alzheimer’s, Parkinson’s drugsThe Wall Street Journal: Pfizer abandons costly hunt for new Alzheimer’s, Parkinson’s drugs
www.marketwatch.com - January 7 at 5:39 PM
Pfizer ends research for new Alzheimers, Parkinsons drugsPfizer ends research for new Alzheimer's, Parkinson's drugs
finance.yahoo.com - January 7 at 4:36 PM
[$$] Pfizer Ends Hunt for Drugs to Treat Alzheimers and Parkinsons[$$] Pfizer Ends Hunt for Drugs to Treat Alzheimer's and Parkinson's
finance.yahoo.com - January 6 at 4:32 PM
Analyzing SCYNEXIS (SCYX) & Pfizer (PFE)Analyzing SCYNEXIS (SCYX) & Pfizer (PFE)
www.americanbankingnews.com - January 6 at 10:48 AM
Pfizer’s Revenue and Earnings in 3Q17Pfizer’s Revenue and Earnings in 3Q17
finance.yahoo.com - January 6 at 10:19 AM
A Look at Pfizer’s ValuationA Look at Pfizer’s Valuation
finance.yahoo.com - January 5 at 4:16 PM
How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
finance.yahoo.com - January 5 at 4:16 PM
Pfizer (PFE) Given a $41.00 Price Target at Morgan StanleyPfizer (PFE) Given a $41.00 Price Target at Morgan Stanley
www.americanbankingnews.com - January 5 at 10:54 AM
Pfizer (PFE) Reports Research Collaboration and License Agreement with Berkeley LightsPfizer (PFE) Reports Research Collaboration and License Agreement with Berkeley Lights
www.streetinsider.com - January 5 at 10:33 AM
Pfizer Is Pursuing Oncology, Inflammation, and Immunology ResearchPfizer Is Pursuing Oncology, Inflammation, and Immunology Research
finance.yahoo.com - January 4 at 4:34 PM
[$$] The Dow Has What Investors Want[$$] The Dow Has What Investors Want
finance.yahoo.com - January 4 at 4:34 PM
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in DecemberThe Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
finance.yahoo.com - January 4 at 4:34 PM
Arvinas Sees $830 Mln Upfront, Potential Milestone Payments In Deal With PfizerArvinas Sees $830 Mln Upfront, Potential Milestone Payments In Deal With Pfizer
www.nasdaq.com - January 4 at 10:20 AM
Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announced Collaboration for ALS Treatments; $12M UpfrontSangamo Therapeutics (SGMO) and Pfizer (PFE) Announced Collaboration for ALS Treatments; $12M Upfront
www.streetinsider.com - January 4 at 10:20 AM
Pfizer (PFE) Collaborates With Sangamo for Gene TherapyPfizer (PFE) Collaborates With Sangamo for Gene Therapy
www.zacks.com - January 4 at 10:20 AM
Berkeley Lights Announces Research Collaboration and License Agreement with PfizerBerkeley Lights Announces Research Collaboration and License Agreement with Pfizer
finance.yahoo.com - January 4 at 10:20 AM
What Were the Key Developments in Pfizer’s Research Pipeline in 2017?What Were the Key Developments in Pfizer’s Research Pipeline in 2017?
finance.yahoo.com - January 4 at 10:20 AM
Bavencio May Prove to Be a Strong Growth Driver for PfizerBavencio May Prove to Be a Strong Growth Driver for Pfizer
finance.yahoo.com - January 4 at 10:20 AM
Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug CandidatesArvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates
www.prnewswire.com - January 4 at 12:34 AM
Biggest Blockbuster Drugs of All TimeBiggest Blockbuster Drugs of All Time
finance.yahoo.com - January 3 at 4:35 PM

SEC Filings

Pfizer (NYSE:PFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pfizer (NYSE PFE) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.